Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83


Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells.

Bowler E, Porazinski S, Uzor S, Thibault P, Durand M, Lapointe E, Rouschop KMA, Hancock J, Wilson I, Ladomery M.

BMC Cancer. 2018 Apr 2;18(1):355. doi: 10.1186/s12885-018-4227-7.


The DNA methyl-transferase protein DNMT1 enhances tumor-promoting properties of breast stromal fibroblasts.

Al-Kharashi LA, Al-Mohanna FH, Tulbah A, Aboussekhra A.

Oncotarget. 2017 Dec 18;9(2):2329-2343. doi: 10.18632/oncotarget.23411. eCollection 2018 Jan 5.


A comparative study of anti-aging properties and mechanism: resveratrol and caloric restriction.

Li J, Zhang CX, Liu YM, Chen KL, Chen G.

Oncotarget. 2017 Aug 9;8(39):65717-65729. doi: 10.18632/oncotarget.20084. eCollection 2017 Sep 12.


Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis.

Lee SK, Park KK, Kim HJ, Park J, Son SH, Kim KR, Chung WY.

Sci Rep. 2017 Aug 29;7(1):9610. doi: 10.1038/s41598-017-09040-4.


RNA-editing enzymes ADAR1 and ADAR2 coordinately regulate the editing and expression of Ctn RNA.

Anantharaman A, Gholamalamdari O, Khan A, Yoon JH, Jantsch MF, Hartner JC, Gorospe M, Prasanth SG, Prasanth KV.

FEBS Lett. 2017 Sep;591(18):2890-2904. doi: 10.1002/1873-3468.12795. Epub 2017 Aug 30.


Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.

Giaginis C, Sampani A, Kotta-Loizou I, Giannopoulou I, Danas E, Politi E, Tsourouflis G, Kouraklis G, Patsouris E, Keramopoulos A, Nakopoulou L, Theocharis S.

Pathol Oncol Res. 2018 Jul;24(3):631-640. doi: 10.1007/s12253-017-0288-1. Epub 2017 Aug 14.


The RNA-binding protein HuR inhibits expression of CCL5 and limits recruitment of macrophages into tumors.

Brauß TF, Winslow S, Lampe S, Scholz A, Weigert A, Dehne N, von Stedingk K, Schmid T, Brüne B.

Mol Carcinog. 2017 Dec;56(12):2620-2629. doi: 10.1002/mc.22706. Epub 2017 Jul 28.


Oncogenic Protein Kinase D3 Regulating Networks in Invasive Breast Cancer.

Liu Y, Li J, Zhang J, Yu Z, Yu S, Wu L, Wang Y, Gong X, Wu C, Cai X, Mo L, Wang M, Gu J, Chen L.

Int J Biol Sci. 2017 May 16;13(6):748-758. doi: 10.7150/ijbs.18472. eCollection 2017.


Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.

Tan S, Ding K, Chong QY, Zhao J, Liu Y, Shao Y, Zhang Y, Yu Q, Xiong Z, Zhang W, Zhang M, Li G, Li X, Kong X, Ahmad A, Wu Z, Wu Q, Zhao X, Lobie PE, Zhu T.

J Biol Chem. 2017 Aug 18;292(33):13551-13564. doi: 10.1074/jbc.M117.780973. Epub 2017 Jun 21.


HuR promotes breast cancer cell proliferation and survival via binding to CDK3 mRNA.

Zhang Z, Huang A, Zhang A, Zhou C.

Biomed Pharmacother. 2017 Jul;91:788-795. doi: 10.1016/j.biopha.2017.04.063. Epub 2017 May 10.


Oncogenic p95HER2 regulates Na+-HCO3- cotransporter NBCn1 mRNA stability in breast cancer cells via 3'UTR-dependent processes.

Gorbatenko A, Olesen CW, Loebl N, Sigurdsson HH, Bianchi C, Pedraz-Cuesta E, Christiansen J, Pedersen SF.

Biochem J. 2016 Nov 1;473(21):4027-4044. Epub 2016 Sep 8.


Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment.

Kotta-Loizou I, Vasilopoulos SN, Coutts RH, Theocharis S.

Neoplasia. 2016 Nov;18(11):674-688. doi: 10.1016/j.neo.2016.09.002. Epub 2016 Oct 18. Review.


HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy.

Mehta M, Basalingappa K, Griffith JN, Andrade D, Babu A, Amreddy N, Muralidharan R, Gorospe M, Herman T, Ding WQ, Ramesh R, Munshi A.

Oncotarget. 2016 Oct 4;7(40):64820-64835. doi: 10.18632/oncotarget.11706.


Regulation of nucleolin expression by miR-194, miR-206, and HuR.

Bose S, Tholanikunnel TE, Reuben A, Tholanikunnel BG, Spicer EK.

Mol Cell Biochem. 2016 Jun;417(1-2):141-53. doi: 10.1007/s11010-016-2721-2. Epub 2016 May 25.


The Ribonucleic Complex HuR-MALAT1 Represses CD133 Expression and Suppresses Epithelial-Mesenchymal Transition in Breast Cancer.

Latorre E, Carelli S, Raimondi I, D'Agostino V, Castiglioni I, Zucal C, Moro G, Luciani A, Ghilardi G, Monti E, Inga A, Di Giulio AM, Gorio A, Provenzani A.

Cancer Res. 2016 May 1;76(9):2626-36. doi: 10.1158/0008-5472.CAN-15-2018. Epub 2016 Apr 20.


Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins.

Hitti E, Bakheet T, Al-Souhibani N, Moghrabi W, Al-Yahya S, Al-Ghamdi M, Al-Saif M, Shoukri MM, Lánczky A, Grépin R, Győrffy B, Pagès G, Khabar KS.

Cancer Res. 2016 Jul 15;76(14):4068-80. doi: 10.1158/0008-5472.CAN-15-3110. Epub 2016 May 17.


Dual mechanisms of action of the RNA-binding protein human antigen R explains its regulatory effect on melanoma cell migration.

Moradi F, Berglund P, Linnskog R, Leandersson K, Andersson T, Prasad CP.

Transl Res. 2016 Jun;172:45-60. doi: 10.1016/j.trsl.2016.02.007. Epub 2016 Feb 23.


Dihydrotanshinone-I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function.

D'Agostino VG, Lal P, Mantelli B, Tiedje C, Zucal C, Thongon N, Gaestel M, Latorre E, Marinelli L, Seneci P, Amadio M, Provenzani A.

Sci Rep. 2015 Nov 10;5:16478. doi: 10.1038/srep16478.


The Expression of CUGBP1 After Spinal Cord Injury in Rats.

Yang L, Zhang J, Chen J, Jin H, Liu J, Huang S, Cui Z.

Neurochem Res. 2015 Sep;40(9):1966-75. doi: 10.1007/s11064-015-1692-0. Epub 2015 Aug 18.


Assembly of a comprehensive regulatory network for the mammalian circadian clock: a bioinformatics approach.

Lehmann R, Childs L, Thomas P, Abreu M, Fuhr L, Herzel H, Leser U, Relógio A.

PLoS One. 2015 May 6;10(5):e0126283. doi: 10.1371/journal.pone.0126283. eCollection 2015.

Supplemental Content

Loading ...
Support Center